

# AQUARRAY HAS MADE GREAT STEPS FORWARD



**AFTER WINNING AN SME INSTRUMENTS GRANT WITHIN THE HORIZON 2020 FRAMEWORK, AQUARRAY IS PUSHING THE FURTHER DEVELOPMENT OF ITS DROPLET MICROARRAY TECHNOLOGY.**

Aquarray has been selected for an SME Instruments grant within the Horizon 2020 framework of the European Union. With a multi-million budget, Aquarray is able to further develop the Droplet Microarray (DMA) for personalised medicine applications.

The DMA is Aquarray's patented technology for miniaturized cell cultivation, ultra-high throughput screening (uHTS) and biochemical assay platforms. The DMA delivers the potential of microarray technologies to the field of cell based screening systems. Aquarray opens multiplexing opportunities to research areas all the way from basic research through industrial uHTS to clinical applications.

The new CEO, Dr. Wolfgang Sipos, who started his career with Roche Diagnostics and has successfully built up and sold own businesses in the life science area, will lead the team of Dr. Pavel Levkin, who is group leader of the Multifunctional Materials Systems research group at the Karlsruhe Institute of Technology (KIT).

The grant was possible, without external investors, through funding by the founders and the new CEO, whereby a large part was financed by Prof. Dr. Gunter Festel, who is a business angel and a co-founder of Aquarray.

## **ABOUT AQUARRAY**

Aquarray is a spin-off of the Karlsruhe Institute of Technology (KIT), founded in April 2018, based on the scientific work of Dr. Pavel Levkin and with the support of the EXIST Research Funding programme of the German Ministry of Economics and ERC Proof-of-Concept grant of EU.

**Contact for more information:** Dr. Wolfgang Sipos, [wolfgang.sipos@aquarray.com](mailto:wolfgang.sipos@aquarray.com)



Aquarray has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 880019.